PerkinElmer to Acquire EUROIMMUN for Approximately $1.3 Billion
News Jun 19, 2017
PerkinElmer has entered into a definitive agreement to acquire EUROIMMUN Medical Laboratory Diagnostics AG. The agreement provides that PerkinElmer will acquire up to a 100% stake in EUROIMMUN. The total purchase price of the transaction based on all outstanding shares being acquired will be approximately $1.3 billion in cash.
Based in Lübeck, Germany, with approximately 2,400 employees, EUROIMMUN is widely recognized as a global leader in autoimmune testing and an emerging force in infectious disease and allergy testing. The company has extensive expertise and capabilities across immunology, cell biology, histology, biochemistry and molecular biology. EUROIMMUN is expected to generate approximately $310 million in revenue this year, and over the last five years, the company has averaged revenue growth of 19%. In 2016, the company generated sales in more than 130 countries worldwide, with approximately 45% of revenues in China, 30% in Europe, Middle East & Africa, 5% in the Americas and 20% in Rest of World.
The acquisition combines two innovative, results-driven cultures with a shared mission of improving global health. The combination expands PerkinElmer's reach into autoimmune and allergy diagnostic markets, while offering new infectious disease capabilities to customers in China. In addition, as a market leader in the U.S. for reproductive health, PerkinElmer will have the opportunity to drive EUROIMMUN's solutions into this well-established channel.
"With the acquisition of EUROIMMUN and its talented team of professionals, we are able to leverage our combined advanced detection, imaging and assay development capabilities, along with our strong collective market positions and synergistic commercial activities, to deliver better and more complete solutions to our customers around the world," said Robert Friel, chairman and chief executive officer of PerkinElmer. "We look forward to working with the EUROIMMUN team as we partner together to help improve global health through advanced diagnostics."
"I am delighted to entrust EUROIMMUN to PerkinElmer, a company I believe shares our important mission and will secure the continuity of our culture and tradition of innovation that we have developed over the last thirty years," said Professor Winfried Stöcker, founder and chief executive officer of EUROIMMUN.
PerkinElmer's comprehensive global diagnostics portfolio will now include solutions focused on: reproductive health; autoimmune, infectious disease and allergy testing; gene analyses; and genomics offerings for oncology and other molecular tests through its wide range of instruments, reagents, assay platforms and software offerings.
Innate Reaction of Hematopoietic Stem Cells to Severe InfectionsNews
Researchers at the University of Zurich have shown for the first time that hematopoietic stem cells detect infectious agents themselves and begin to divide, without signals from growth factors.READ MORE
CRISPR Reveals New Targets for Promising Cancer DrugsNews
Novel screening method identifies new drug targets that could potentially enhance the effectiveness of PD-1 checkpoint inhibitors, a promising new class of cancer immunotherapy.READ MORE
New Way Found to Boost Immunity in Fighting Cancer and InfectionsNews
Researchers have identified a key new mechanism that regulates the ability of T-cells of the immune system to react against foreign antigens and cancer.READ MORE
Comments | 0 ADD COMMENT
EMBL Course: Transgenic Animals - Micromanipulation Techniques
Apr 10 - Apr 11, 2018
EMBO Practical Course: Extracellular Vesicles: From Biology to Biomedical Applications
Apr 09 - Apr 13, 2018
EMBO | EMBL Symposium: Tissue Self-Organisation: Challenging the Systems
Mar 11 - Mar 14, 2018